Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomewide Screen Reveals Potential Synergistic Partners for FLT3 Mutant Myeloid Leukemia

ABSTRACT: CRISPR knockout screening on MOLM-13 cells with midostaurin or gilteritinib

ORGANISM(S): Homo sapiens

PROVIDER: GSE143314 | GEO | 2020/01/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genomewide Screen Reveals Potential Synergistic Partners for FLT3 Mutant Myeloid Leukemia

Project description:Genomewide Screen Reveals Potential Synergistic Partners for FLT3 Mutant Myeloid Leukemia

| PRJNA600003 | ENA

BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors

Project description:While clinical benefit has been observed with gilteritinib, most patients relapse through unknown mechanisms. To investigate mechanisms of gilteritinib resistance, we performed targeted genomic sequencing and single cell (sc) RNASeq on primary FLT3-ITD-mutated AML samples. Co-occurring mutations in RAS pathway genes were the most common. In gilteritinib-unresponsive patients, increased expression of bone marrow-derived hematopoietic cytokines and chemokines was observed after treatment compared to gilteritinib-sensitive patients. Expression of the TEK-family kinase, BMX, was higher in gilteritinib-unresponsive patients after treatment compared to gilteritinib-sensitive patients. BMX contributed to gilteritinib resistance in FLT3-mutant cells lines in a hypoxia-dependent manner by promoting pSTAT5 signaling, which was reversed with pharmacological inhibition and genetic knockout. In primary FLT3-mutated AML samples, pharmacological inhibition of BMX enhanced the antileukemic activity of gilteritinib and decreased chemokine expression. Gene module analysis associated gilteritinib responsiveness with lymphocyte differentiation and myeloid leukocyte activation. By contrast, unresponsiveness to gilteritinib associated with upregulation of cell-cycle, DNA/RNA metabolic processes, and protein translation. Together, these data support a role for microenvironment-mediated factors modulated by BMX in the escape from targeted therapy and gilteritinib resistance. This analysis provides a deeper understanding of targets and pathways for potential therapeutic intervention to restore gilteritinib sensitivity.

2022-07-07 | GSE199333 | GEO

Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition

Project description:CRISPR knockout screening on MOLM-13 cells with KPT-9274

2021-01-27 | GSE162473 | GEO

RNA sequestration in P-bodies sustains myeloid leukemia [small RNA-seq]

Project description:To investigate small non-coding RNA changes in AML cells following loss of P-bodies, we knocked down DDX6 in MOLM-13 cells.

2024-07-12 | GSE224851 | GEO

The interplay between RNA sequestration in P-bodies and chromatin architecture sustains myeloid leukemia

Project description:To investigate chromatin remodeling in AML cells following loss of P-bodies, we knocked down DDX6 in MOLM-13 cells.

2024-08-09 | GSE224931 | GEO

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia

Project description:Purpose: Compare transcriptional changes between drug treated (gilteritinib, TP-0903) and vehicle in acute myeloid leukemia xenografts. Methods: FLT3-ITD+ MOLM13-RES-Luc+ (MOLM13 cells with a D835Y mutation generating a resistant phenotype) AML cells were xenografted into NSG mice. Mice were randomized according to bioluminescence imaging, and treatment of FLT3 tyrosine kinase inhibitor (gilteritinib, 30 mg/kg, once daily for 5 days/week) was started on day 13 post-tail vein injection. At study end point, mice were humanely euthanized and bone marrow was collected. AML cells (human CD45+) were isolated, and ATAC-seq was performed on HiSeq 4000, total RNA. Sequencing reads were aligned and analyzed for differential gene expression of treatment vs vehicle cohorts. Results: The analysis revealed the chromatin accessibility changes induced by gilteritinib in MOLM13-RES AML xenograft model.

2021-07-07 | GSE179421 | GEO

RNA profiles of MOLM-13 cells treated with FLT3 inhibitor in the presence of conditioned media of bone marrow stromal cells

Project description:RNA-seq analysis of MOLM-13 cells to compare the gene expression profiles post FLT3 inhibition and/or ATM inhibition in the presence or absence of conditioned media of bone marrow stromal cell HS-5

2022-10-19 | GSE202229 | GEO

The interplay between RNA sequestration in P-bodies and chromatin architecture sustains myeloid leukemia [CUT&RUN]

Project description:To investigate chromatin remodeling in AML cells following loss of P-bodies, we knocked down DDX6 in MOLM-13 cells.

2024-08-11 | GSE261265 | GEO

RNA-seq of MOLM-13 acute myeloid leukemia cell line treated with FIDAS-5

Project description:MOLM-13 acute myeloid leukemia cells were treated with 3 µM FIDAS-5 methionine S-adenosyltransferase 2A (MAT2A) inhibitor or 0.1% DMSO as control for 48 hours

2023-04-22 | E-MTAB-12847 | biostudies-arrayexpress

Potential targeting of FLT3 acute myeloid leukemia.

Project description:Aberrant FLT3 receptor signaling is common in acute myeloid leukemia (AML) and has important implications for the biology and clinical management of the disease. Patients with FLT3-mutated AML frequently present with critical illness, are more likely to relapse after treatment, and have worse clinical outcomes than their FLT3 wild type counterparts. The clinical management of FLT3-mutated AML has been transformed by the development of FLT3 inhibitors, which are now in use in the frontline and relapsed/refractory settings. However, many questions regarding the optimal approach to the treatment of these patients remain. In this paper, we will review the rationale for targeting the FLT3 receptor in AML, the impact of FLT3 mutation on patient prognosis, the current standard of care approaches to FLT3-mutated AML management, and the diverse array of FLT3 inhibitors in use and under investigation. We will also explore new opportunities and strategies for targeting the FLT3 receptor. These include targeting the receptor in patients with non-canonical FLT3 mutations or wild type FLT3, pairing FLT3 inhibitors with other novel therapies, using minimal residual disease (MRD) testing to guide the targeting of FLT3, and novel immunotherapeutic approaches.

| S-EPMC7927884 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data